BioNano Genomics Inc vs Commvault Systems Inc — how do they compare? BioNano Genomics Inc trades at $1.2 (market cap $13.66M), while Commvault Systems Inc trades at $140.6 (market cap $5.78B). The key difference: Commvault Systems Inc is far larger — about 423.1× BioNano Genomics Inc's market cap, and Commvault Systems Inc is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| BNGO | CVLT | |
|---|---|---|
Market Cap | $13.66M | $5.78B |
Sector | Health | Technology |
52-Week High | $4.92 | $195.41 |
52-Week Low | $1.06 | $75.18 |
Enterprise Value | $16.26M | $5.76B |
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.19, up 2.59% today, with bullish technical signals from moving averages. The company shows improving financials with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable. Recent earnings have consistently beaten expectations, and analyst sentiment is positive with 57% buy ratings. Key developments include debt retirement and scientific publications highlighting optical genome mapping adoption.
The outlook is cautiously optimistic given improving fundamentals and positive analyst coverage, but significant risks remain due to persistent losses and negative cash flow. Investment opportunity lies in the company's technology adoption growth, while primary risks include profitability challenges and competitive pressures in the genomics space.
Commvault Systems (CVLT) trades at $139.36, down slightly by 0.05% on the day, with strong technical momentum showing a bullish moving average signal. The company has consistently beaten earnings expectations in recent quarters, with Q2 2026 EPS of $1.42 surpassing the $1.16 estimate. Recent positive developments include the integration of Threat Scan with Google Threat Intelligence and a partnership with Microsoft for AI security on Azure, driving investor optimism despite a shareholder investigation announcement.
CVLT presents a mixed fundamental picture with robust revenue growth and strong profitability metrics but elevated valuation multiples. The stock offers significant upside to the consensus price target of $172.40, supported by 54.5% analyst buy ratings. Key risks include high P/E ratio of 89.35, ongoing fiduciary investigation, and potential margin compression as revenue growth outpaces net income growth in 2026 projections.
Trailing returns across standard periods
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →Commvault provides enterprise-grade data protection and information management software. Its platform helps businesses manage, back up, and recover data across on-premises, cloud, and hybrid environments.
Read more on CVLT →